LP433806-9
NAT2 gene targeted mutation analysis
Active
Description
N-acetyltransferase type 2 is one of the first and most studied enzyme for its pharmacogenetics traits and how they differ between individuals. It is a polymorphic phase 2 metabolic enzyme whose role is to combine hydrazine derivatives with acetyl groups in aromatic amine drugs, and in a number of toxins and carcinogens found in the diet, cigarette smoke, and the environment. In addition, possible correlations between the N-acetyl phenotype and human disease have been studied, and the most compelling of those associations include urinary bladder cancer and familial Parkinson's disease. PMID: 15932650 NAT2 has 36 known haplotype alleles that determine whether an individual is a fast, intermediate, or slow acetylator phenotype. The percentage of individuals who are slow acetylators is highest as one gets closer to the equator. Eighty percent of individuals close to the equator are slow acetylators, while only 10% of individuals located far from the equator are slow acetylators. PMID: 9255557 Isoniazid is the most effective treatment for tuberculosis and is acetylated by NAT2 to form a non-toxic metabolite. Slow acetylators taking isoniazid are at risk of hepatotoxicity. PMID: 9154882 Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- NAT2 gene targeted mutation analysis
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2022-10-12
- Construct for LOINC Short Name
- N-acetyltransferase 2
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP433806-9
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright